Development of novel entry inhibitors targeting emerging viruses.
Identifieur interne : 001D35 ( Main/Exploration ); précédent : 001D34; suivant : 001D36Development of novel entry inhibitors targeting emerging viruses.
Auteurs : Yanchen Zhou [États-Unis] ; Graham SimmonsSource :
- Expert review of anti-infective therapy [ 1744-8336 ] ; 2012.
Descripteurs français
- KwdFr :
- MESH :
- pharmacologie : Antiviraux.
- physiologie : Récepteurs viraux.
- virologie : Maladies transmissibles émergentes.
- Antiviraux, Attachement viral, Interactions hôte-pathogène, Pénétration virale, Récepteurs viraux, Tests de criblage à haut débit.
English descriptors
- KwdEn :
- Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Communicable Diseases, Emerging (virology), High-Throughput Screening Assays, Host-Pathogen Interactions (drug effects), Receptors, Virus (drug effects), Receptors, Virus (physiology), Virus Attachment (drug effects), Virus Internalization (drug effects).
- MESH :
- chemical , chemistry : Antiviral Agents.
- chemical , drug effects : Receptors, Virus.
- chemical , pharmacology : Antiviral Agents.
- drug effects : Host-Pathogen Interactions, Virus Attachment, Virus Internalization.
- chemical , physiology : Receptors, Virus.
- virology : Communicable Diseases, Emerging.
- High-Throughput Screening Assays.
Abstract
Emerging viral diseases pose a unique risk to public health, and thus there is a need to develop therapies. A current focus of funding agencies, and hence research, is the development of broad-spectrum antivirals, and in particular, those targeting common cellular pathways. The scope of this article is to review screening strategies and recent advances in this area, with a particular emphasis on antivirals targeting the step of viral entry for emerging lipid-enveloped viruses such as Ebola virus and SARS-coronavirus.
DOI: 10.1586/eri.12.104
PubMed: 23199399
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001282
- to stream PubMed, to step Curation: 001282
- to stream PubMed, to step Checkpoint: 001362
- to stream Ncbi, to step Merge: 002591
- to stream Ncbi, to step Curation: 002591
- to stream Ncbi, to step Checkpoint: 002591
- to stream Main, to step Merge: 001D58
- to stream Main, to step Curation: 001D35
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of novel entry inhibitors targeting emerging viruses.</title><author><name sortKey="Zhou, Yanchen" sort="Zhou, Yanchen" uniqKey="Zhou Y" first="Yanchen" last="Zhou">Yanchen Zhou</name><affiliation wicri:level="2"><nlm:affiliation>Blood Systems Research Institute and Department of Laboratory Medicine, University of California, San Francisco, 270 Masonic Avenue, San Francisco, CA 94118, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Blood Systems Research Institute and Department of Laboratory Medicine, University of California, San Francisco, 270 Masonic Avenue, San Francisco, CA 94118</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:23199399</idno><idno type="pmid">23199399</idno><idno type="doi">10.1586/eri.12.104</idno><idno type="wicri:Area/PubMed/Corpus">001282</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001282</idno><idno type="wicri:Area/PubMed/Curation">001282</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001282</idno><idno type="wicri:Area/PubMed/Checkpoint">001362</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001362</idno><idno type="wicri:Area/Ncbi/Merge">002591</idno><idno type="wicri:Area/Ncbi/Curation">002591</idno><idno type="wicri:Area/Ncbi/Checkpoint">002591</idno><idno type="wicri:Area/Main/Merge">001D58</idno><idno type="wicri:Area/Main/Curation">001D35</idno><idno type="wicri:Area/Main/Exploration">001D35</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of novel entry inhibitors targeting emerging viruses.</title><author><name sortKey="Zhou, Yanchen" sort="Zhou, Yanchen" uniqKey="Zhou Y" first="Yanchen" last="Zhou">Yanchen Zhou</name><affiliation wicri:level="2"><nlm:affiliation>Blood Systems Research Institute and Department of Laboratory Medicine, University of California, San Francisco, 270 Masonic Avenue, San Francisco, CA 94118, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Blood Systems Research Institute and Department of Laboratory Medicine, University of California, San Francisco, 270 Masonic Avenue, San Francisco, CA 94118</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name></author></analytic><series><title level="j">Expert review of anti-infective therapy</title><idno type="eISSN">1744-8336</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (chemistry)</term><term>Antiviral Agents (pharmacology)</term><term>Communicable Diseases, Emerging (virology)</term><term>High-Throughput Screening Assays</term><term>Host-Pathogen Interactions (drug effects)</term><term>Receptors, Virus (drug effects)</term><term>Receptors, Virus (physiology)</term><term>Virus Attachment (drug effects)</term><term>Virus Internalization (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux ()</term><term>Antiviraux (pharmacologie)</term><term>Attachement viral ()</term><term>Interactions hôte-pathogène ()</term><term>Maladies transmissibles émergentes (virologie)</term><term>Pénétration virale ()</term><term>Récepteurs viraux ()</term><term>Récepteurs viraux (physiologie)</term><term>Tests de criblage à haut débit</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Host-Pathogen Interactions</term><term>Virus Attachment</term><term>Virus Internalization</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Récepteurs viraux</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Virus</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Maladies transmissibles émergentes</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Communicable Diseases, Emerging</term></keywords><keywords scheme="MESH" xml:lang="en"><term>High-Throughput Screening Assays</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Antiviraux</term><term>Attachement viral</term><term>Interactions hôte-pathogène</term><term>Pénétration virale</term><term>Récepteurs viraux</term><term>Tests de criblage à haut débit</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Emerging viral diseases pose a unique risk to public health, and thus there is a need to develop therapies. A current focus of funding agencies, and hence research, is the development of broad-spectrum antivirals, and in particular, those targeting common cellular pathways. The scope of this article is to review screening strategies and recent advances in this area, with a particular emphasis on antivirals targeting the step of viral entry for emerging lipid-enveloped viruses such as Ebola virus and SARS-coronavirus.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><noCountry><name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name></noCountry><country name="États-Unis"><region name="Californie"><name sortKey="Zhou, Yanchen" sort="Zhou, Yanchen" uniqKey="Zhou Y" first="Yanchen" last="Zhou">Yanchen Zhou</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D35 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D35 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23199399
|texte= Development of novel entry inhibitors targeting emerging viruses.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23199399" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |